Currently, there are 2.04B common shares owned by the public and among those 2.04B shares have been available to trade.
The company’s stock has a 5-day price change of -5.54% and -17.38% over the past three months. GSK shares are trading -5.14% year to date (YTD), with the 12-month market performance down to -19.07% lower. It has a 12-month low price of $32.55 and touched a high of $45.92 over the same period. GSK has an average intraday trading volume of 5.35 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.71%, -6.84%, and -18.60% respectively.
Institutional ownership of GSK Plc ADR (NYSE: GSK) shares accounts for 15.19% of the company’s 2.04B shares outstanding.
It has a market capitalization of $65.45B and a beta (3y monthly) value of 0.64. The stock’s trailing 12-month PE ratio is 20.87, while the earnings-per-share (ttm) stands at $1.54. The company has a PEG of 3.76 and a Quick Ratio of 0.53 with the debt-to-equity ratio at 1.15. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.39% over the week and 1.37% over the month.
Analysts forecast that GSK Plc ADR (GSK) will achieve an EPS of 0.48 for the current quarter, 0 for the next quarter and 4.13 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.47 while analysts give the company a high EPS estimate of 0.47. Comparatively, EPS for the current quarter was 0.73 a year ago. Earnings per share for the fiscal year are expected to decrease by -1.17%, and 4.74% over the next financial year. EPS should grow at an annualized rate of 5.56% over the next five years, compared to 4.23% over the past 5-year period.
Jefferies coverage for the GSK Plc ADR (GSK) stock in a research note released on November 12, 2024 offered a Hold rating with a price target of $39.50. Goldman on their part issued Neutral rating on May 30, 2024.
